Aflibercept in combination with FOLFIRI as first-line chemotherapy in patients with metastatic colorectal cancer (mCRC): a phase II study (FFCD 1302)
A Lapeyre-Prost, S Pernot, J Sigrand… - Clinical Colorectal …, 2020 - Elsevier
Abstract Background FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin)+ aflibercept
improves median overall survival (OS) and progression-free survival (PFS) in patients with …
improves median overall survival (OS) and progression-free survival (PFS) in patients with …
Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302)
A Lapeyre-Prost, S Pernot, J Sigrand… - Clinical Colorectal …, 2020 - Elsevier
Abstract Background FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin)+ aflibercept
improves median overall survival (OS) and progression-free survival (PFS) in patients with …
improves median overall survival (OS) and progression-free survival (PFS) in patients with …
Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302)
A Lapeyre-Prost, S Pernot… - Clinical …, 2020 - clinical-colorectal-cancer.com
Abstract Background FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin)+ aflibercept
improves median overall survival (OS) and progression-free survival (PFS) in patients with …
improves median overall survival (OS) and progression-free survival (PFS) in patients with …
Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).
A Lapeyre-Prost, S Pernot, J Sigrand… - Clinical Colorectal …, 2020 - europepmc.org
Background FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin)+ aflibercept improves
median overall survival (OS) and progression-free survival (PFS) in patients with previously …
median overall survival (OS) and progression-free survival (PFS) in patients with previously …
[引用][C] Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302)
A Lapeyre-Prost, S Pernot, J Sigrand… - Clinical Colorectal …, 2020 - hal.science
Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic
Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302) - Archive ouverte HAL Accéder …
Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302) - Archive ouverte HAL Accéder …
Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302)
A Lapeyre-Prost, S Pernot, J Sigrand… - Clinical …, 2020 - pubmed.ncbi.nlm.nih.gov
Background FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin)+ aflibercept improves
median overall survival (OS) and progression-free survival (PFS) in patients with previously …
median overall survival (OS) and progression-free survival (PFS) in patients with previously …
[引用][C] Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302)
A Lapeyre-Prost, S Pernot, J Sigrand… - Clinical Colorectal …, 2020 - univ-angers.hal.science
Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic
Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302) - Université d'Angers Accéder …
Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302) - Université d'Angers Accéder …
[PDF][PDF] Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302)
A Lapeyre-Prost, S Pernot, J Sigrand, K Le Malicot… - Clinical Colorectal …, 2020 - ffcd.fr
Abstract Chemotherapy with FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) D
aflibercept improves survival in patients with previously treated metastatic colorectal cancer …
aflibercept improves survival in patients with previously treated metastatic colorectal cancer …